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erythematosus patient receiving steroid therapy.
Background. Active systemic lupus erythematosus (SLE)
can cause fever. Steroids (glucocorticoids) suppress SLE fever;
however, the extent to which steroid therapy affects SLE fever
not previously been rigorously studied.
Methods. Study A is a prospective study of recurrently active
SLE patients (N = 92, 60 renal SLE and 32 nonrenal SLE) who
recorded daily oral evening temperatures while participating in
a longitudinal study of risk factors for SLE flare. Study B is a
retrospective study of consecutive febrile SLE patients (N =
22) who received steroids initially because SLE was suspected.
At final analysis 11 had SLE fever and 11 had infection fever.
Results. In study A during a mean follow-up of 13.2 ± 8.1
months, 51 of the 92 patients experienced 73 SLE flares. In only
one patient was SLE fever associated with SLE flare. In the
other 50 patients who flared, there was no significant trend to
develop fever prior to or at the onset of SLE flare. Prednisone,
median dose 10 mg, was being received at 82% of the study vis-
its at which an SLE flare was declared. In study B, prednisone
28 mg (range 20 to 40 mg) completely suppressed SLE fever,
usually within 24 hours. In contrast, infection fever persisted
despite prednisone 35 to 300 mg/day. Of those with infection
fever, three developed fatal sepsis when high-dose steroid ther-
apy was continued.
Conclusion. In SLE patients receiving prednisone at main-
tenance doses or greater, SLE fever is rare. When fever does
develop, it is usually due to infection. Continuing high steroid
dose steroid therapy in those with infection fever may increase
the risk of severe sepsis.
Fever is believed to be a common manifestation of ac-
tive systemic lupus erythematosus (SLE) fever. In the
report of Harvey et al [1] from the early 1950s, fever at-
tributed to active SLE occurred in 86% of patients. How-
Key words: SLE, fever, steroid therapy.
Received for publication July 16, 2004
and in revised form September 27, 2004, and November 24, 2004
Accepted for publication March 8, 2005
C© 2005 by the International Society of Nephrology
ever, over the ensuing decades the reported incidence of
fever attributed to SLE has declined progressively (re-
viewed in [2]). For example, in SLE patients studied be-
tween 1980 and 1989, only 41% reported fever as a sign
of active SLE [3]. Wallace [2] suggests that the recent
decline in the incidence of SLE fever may result from
the more frequent use of nonsteroidal anti-inflammatory
drug (NSAID) therapy. The present work tests the hy-
pothesis that glucocorticoid (steroid) therapy also can
contribute to the declining incidence of SLE fever. Study
A tested this hypothesis prospectively in a cohort with re-
currently active SLE in which, at any given time, an aver-
age of 75% were receiving steroid therapy. Study B tested
this hypothesis retrospectively by determining whether
steroid therapy suppressed SLE fever better than the
fever of infection (infection fever).
Previous work has studied fever in SLE [4–6].
However, none of these studies specifically addressed the
hypotheses of study A or study B. Furthermore, our expe-
rience and that reported by others [7–9] suggests that fatal
sepsis can result when high-dose steroids are continued
in the persistently febrile SLE patients. The reason for
continuing high-dose steroid therapy in the persistently
febrile SLE patients was not stated in the reports; how-
ever, in the patients reported here the managing physi-
cians justified the high-dose steroid therapy because they
assumed that the fever was a sign of active SLE. Thus,
there is a need to better understand the relation of fever
to steroid therapy in the management of SLE. Study A
and study B were undertaken to address this unmet need.
The most rigorous test of the effects of steroid therapy
on SLE fever versus infection fever would be a placebo-
controlled randomized trial. We suggest, however, that
such a study design would be unethical because it would
withhold proven therapy from seriously ill patients. We
suggest that an observational trial design such as that of
study A and study B is the only feasible means to ade-
quately test the study hypotheses regarding the effect of
steroid therapy on SLE fever versus infection fever.
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METHODS
Setting and procedures
Study A. The patients are the first 92 enrolled in the
Ohio SLE Study (OSS), also titled “Pathogenesis of SLE
relapse.” The OSS is the clinical component of the NIH
Program Project entitled “Genetic and clinical risk fac-
tors of human SLE nephritis.” The OSS is a prospective
longitudinal study in which SLE patients with four or
more American College of Rheumatology (ACR) crite-
ria for SLE and recurrently active SLE (two or more
SLE flares requiring an increase in therapy in the previ-
ous three years) or persistently active disease (≥4 months
of active SLE despite therapy consisting of at least pred-
nisone ≥20 mg daily). The patients either had renal SLE
defined as major renal manifestations past or present
with the following characteristics: 24-hour urine pro-
tein/creatinine ratio ≥1.0, serum creatinine ≥1.1 mg/dL
(females) or ≥1.3 mg/dL (males) or both, and attributable
to World Health Organization (WHO) Class III, IV, or
V SLE glomerulonephritis, or nonrenal SLE defined as
never having shown major renal manifestations. The OSS
protocol is as follows.
First, daily testing, which includes a daily log com-
pleted consisting of seven items, including daily evening
oral temperature using an electronic oral thermometer
(Vicks), which was shown to be accurate within +0.5◦F
over the range of 99 to 102◦F by calibration in an elec-
tronic thermocycler (data not shown). Each thermometer
was tested when it was replaced after each 6 to 9 months
of use. The daily log also recorded whether the patient
experienced an infection or other illness that day.
Second, monthly testing, in which a first-voided morn-
ing urine specimen (midmonth for males and amenor-
rheic females) or between days 17 and 25 after the start
of the previous menstrual cycle.
Third, testing each 2 months, which involves the com-
pletion of a systemic lupus activity measure (SLAM),
acute illness report (if illness occurred since the last
study visit), update of the medication list, problem list
and procedure list, and laboratory testing to assess
general status and SLE activation, as follows: 24-hour
urine for protein, creatinine, urea, sodium, semiquan-
titative urinalysis by a study physician (renal SLE
patients only), or dipstick urinalysis (nonrenal SLE pa-
tients only), complete blood count with differential and
platelet count, basic metabolic profile, serum albumin (if
renal SLE), standard plasma chemistries, complement
C3 and C4, antidouble-stranded DNA antibodies, ery-
throcyte sedimentation rate, C-reactive protein, and col-
lection of research specimens frozen at −70◦F (plasma,
serum, urine, urine sediment, and T cell and B cell
fractions).
Fourth, testing each 6 months, including a comprehen-
sive metabolic profile.
Finally, annual testing provides a detailed thrombotic
tendency profile, 24-hour urine for protein, creatinine,
urea, sodium (nonrenal SLE), C-peptide, intact parathy-
roid hormone (PTH), blood lipids, and homocysteine.
Adjudication and classification of SLE relapse. Af-
ter all clinical testing results were assessed from each 2-
month study visit, the OSS Conclusion Form was com-
pleted by the patient’s study physician (L.A.H., K.V.H.,
B.H.R., S.L-W., or D.S.). This form included an assess-
ment of whether an SLE flare (relapse) occurred, and
whether it was renal, nonrenal, or both, and whether the
flare was mild, moderate, or severe. Confirmation of the
flare or no-flare status by independent review of the data
by another study physician was required. Renal relapses
were defined as previously reported [10, 11] as follows.
First, minor relapse, an increase in glomerular hema-
turia from <5 to >15 red blood cells/high-power field with
at least two acanthocytes/high-power field, or recurrence
of one or more red cell casts, leukocyte casts (in the ab-
sence of infection), or a combination of red cell/leukocyte
casts.
Second, moderate relapse is an increase in serum crea-
tinine, proteinuria, or both, attributable to the nephropa-
thy of SLE. If baseline serum creatinine is <2.0 mg/dL,
an increase in serum creatinine of 0.3 to 1.0 mg/dL. If
baseline serum creatinine is ≥2.0, an increase in serum
creatinine of 0.4 to 1.5 mg/dL. Proteinuria relapses were
based on measurement of the protein/creatinine ratio of
a 24-hour urine collection [12] as follows. If baseline pro-
tein/creatinine ratio is <0.5 an increase to ≥1.0. If base-
line urine protein/creatinine ratio is 0.5 to 1.0, an increase
to ≥2.0. If baseline urine protein/creatinine ratio is >1.0,
a doubling of the urine protein/creatinine ratio but the
absolute increase in protein/creatinine ratio is <5.0.
Third, major relapse is an increase in serum creatinine,
urine protein/creatinine ratio, or both and attributable to
the nephropathy of SLE, as follows. If baseline serum cre-
atinine is <2.0 mg/dL, an increase in serum creatinine of
>1.0 mg/dL. If baseline serum creatinine is ≥2.0 mg/dL,
an increase in serum creatinine of >1.5 mg/dL. Finally,
if there is an absolute increase of >5.0 in urine pro-
tein/creatinine ratio.
A nonrenal relapse was declared if the patient devel-
oped symptoms or signs of nonrenal SLE and they were
of sufficient severity that the managing study physician
increased therapy. The method for classifying severity of
nonrenal relapses is as we have previously reported [10,
11] and as supplemented by the British Isle Lupus As-
sessment Group (BILAG) index, which ranked nonre-
nal SLE manifestations as categories A through C[13] as
follows. Minor nonrenal relapse consists in one or more
of the following and attributable to SLE: typical rash,
symmetric mild to moderate arthralgias, fever, thrombo-
cytopenia 50,000 to 100,000/mm3, significant fatigue, oral
ulcers, and mild to moderate hair loss. Moderate nonrenal
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relapse consists in one of more of the following and at-
tributable to SLE: serositis, hemoglobin 9 to 11 g/dL from
hemolysis, platelets 25,000 to 50,000/mm3, neutrophil
count ≤1500/mm3 severe migraine headaches requiring
narcotics for management, seizures in the absence of neu-
rologic deficit, uveitis, retinal cytoid bodies, severe alope-
cia, pericarditis (no tamponade), and extensive mucosal
ulceration. Major nonrenal relapse consists in one or
more of the following and attributable to SLE: pulmonary
hemorrhage, vasculitis of abdominal viscera or brain, se-
vere myositis, platelet count <25,000/mm3 hemoglobin
<9 g/dL, severe rash involving >2/9th body surface area,
aseptic meningitis, transverse myelitis, cerebritis, my-
ocarditis, and pericarditis with tamponade.
Fever definition. In study A fever was defined ei-
ther as an oral temperature >99.6◦F (study fever) or an
oral temperature in the top 10% of all oral temperatures
recorded in that patient (personal fever). Patient tem-
peratures were also recorded at each study visit using the
study clinic’s calibrated electronic oral thermometer.
Study B. The patients (N = 22) are all of the hospital-
ized, febrile, steroid-treated SLE patients cared for by us
or seen by us in consultation at The Ohio State Univer-
sity Medical Center between 1990 and 1998 and in whom
there was sufficient clinical information to allow a defini-
tive analysis regarding the cause of the fever. All met
albumin:creatinine ratio criteria for SLE. Excluded from
study B were three febrile SLE patients who responded
to antimicrobial therapy and to a reduction in glucocorti-
coid therapy. We concluded that their fever was the result
of infection rather than SLE. Nevertheless, they were ex-
cluded from this study because serologic testing to assess
SLE activity was not done.
The steroid doses used in the SLE patients were those
chosen by the patient’s physician to treat the patient’s
perceived illness and not for the purpose of study. All
cases were analyzed retrospectively and after sufficient
time had elapsed to permit a clear determination as to
whether the patient had experienced SLE fever, infection
fever, or indeterminate as defined below.
For study B patients, a normal body temperature was
defined as an oral temperature ≤98.6◦F or a tympanic
membrane temperature ≤99.6◦F. For analysis purposes
tympanic membrane temperatures were converted to the
oral temperature equivalent by subtracting 1◦F.
Definition of infection fever. Infection was deter-
mined to be the cause of the fever if the patient died
of documented sepsis or if all of the following were
present: (1) signs and symptoms of infection was coin-
cident with the fever, (2) the fever and the signs and
symptoms of infection resolved with specific antimicro-
bial therapy or with withdrawal or marked reduction of
steroid and immunosuppressive therapy, and (3) when
the steroid and immunosuppressive therapy were with-
drawn or markedly reduced, SLE flare did not occur dur-
ing the next 4 months of follow-up. The rationale of this
analysis strategy is, if SLE fever was present, withdrawal
of SLE therapy likely would have resulted in an SLE flare
not complete resolution of the patient’s illness.
Definition of SLE fever. SLE was determined to be
the cause of the fever if all of the following were present:
(1) no infection was identified despite extensive testing
which included a detailed physical examination, at least
two out of two negative blood cultures, and a chest x-ray
and urinalysis negative for infection, (2) an illness typical
of active SLE accompanied the fever, and (3) evidence
for infection did not emerge despite the increase in or
addition of steroid therapy.
The above analysis plan should also be able to accu-
rately adjudicate the cause of fever in a patient who has
both an infection and active SLE. For example, if the
febrile illness resolved on antimicrobial therapy and with-
drawal of steroid and immunosuppressive therapy, it can
be concluded that the fever likely was the result of the
infection, not active SLE. The cause of the fever could,
however, be indeterminate. For example, a febrile patient
with both infection and active SLE experiences prompt
resolution of fever with both the start of antimicrobial
therapy and an increase in steroid therapy. We did not,
however, encounter such cases.
Statistical analysis
To assess for fever trends, first we tested whether the
fever variables (study fever, personal fever, or the loga-
rithm of the standard deviation for the daily temperatures
of the preceding 30 days) predicted SLE flare on the visit
date. We used logistic regression models and included
patient type (renal or nonrenal), prednisone usage, race,
and the SLE status of the previous visit as potential co-
variates. Next, we tested whether the fever variables cor-
related with the SLE status on the current or previous
study visit, using linear mixed-effect models. The type of
patient (renal or nonrenal) prednisone usage and race
were also taken into consideration. All other statistical
tests are described in relation to the data. All mean val-
ues are shown ± 1 standard deviation (SD).
RESULTS
Study A
Table 1 shows the demographics and key baseline char-
acteristics of the study A patients. The renal SLE patients
tended to be younger, more likely to be receiving steroid
and immunosuppressive therapy, and less likely to be re-
ceiving NSAIDs, compared to nonrenal SLE patients.
Table 2 shows the SLE flare rate and type during study
follow-up. Of the 92 OSS patients, 51 experienced 73
flares. The flare rate and severity was not significantly
different between the renal and nonrenal SLE patients.
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Table 1. Demographic and key baseline characteristics of systemic
lupus erythematosus (SLE)
Renal SLE Nonrenal SLE
(N = 60) (N = 32) P value
Age years 34.6 40.9 0.0001
Gender Female/male 56/4 29/3 0.6454
Race (Caucasian/African 37/20/3 18/14/0 0.1954
American/other)
% Steroidsa 90 44 <0.0001
% Immunosuppressivesb 85 47 0.0003
% Nonsteroidal 12 47 0.0002
anti-inflammatory drugsc
C3 mg/dLd 90 ± 35 124 ± 39 <0.0001
C4 mg/dLd 16 ± 12 21 ± 10 0.0566
% Anti-double-stranded 29 12 0.0876
DNAe
Serum creatinine mg/dLd 1.22 ± 0.88 0.94 ± 0.79 0.1629
aPrednisone or equivalent.
bImmunosuppressive agents (cyclophosphamide, mycophenolate, methotrex-
ate, azathioprine, leflutamide).
cThese were stopped in all renal SLE patients at their baseline visit.
dMean value ± SD; e% with abnormal level. P values were from t tests for
continuous data, and chi-square (likelihood ratio) tests for categoric data.
Mean study follow-up was 13.2 ± 8.1 months and involved
670 study visits for the 92 patients.
Figure 1 shows the mean daily prednisone dose in the
renal and nonrenal patients during study follow-up. The
renal SLE patients received a significantly higher daily
prednisone dose than the nonrenal patients (P < 0.001).
Prednisone was being taken at 75% of all study visits. For
the study visits in which an SLE flare was declared, 82%
of the patients were receiving prednisone. Of those not
receiving prednisone at the time of SLE flare (N = 13),
two were receiving an NSAID. Thus, at the time of SLE
flares, 85% of patients were receiving either prednisone
or an NSAID. The rate of prednisone use at the time of
SLE flare between renal and nonrenal SLE patients was
not different from that present at baseline (Table 1). Also,
the rate of NSAID use in nonrenal SLE patients at the
time of SLE flare was not different from that present at
baseline (Table 1).
Figure 2 shows the fever trends (defined as study fever
or personal fever) in the 30 days prior to the visits at
which an SLE flare was declared, compared to the study
visits in which no SLE flare was declared. As can be seen,
the fever trends were not different between flare and no
flare visits. Also not affecting the fever trends before flare
and no flare visits was changing the definition of personal
fever to temperatures ≥ the top 5% of the individual’s
temperature, whether the SLE flare was renal or non-
renal, the patients’ race, or expressing temperature as a
logarithm of the standard deviation of the daily tempera-
ture during the 30 days prior to each study visit (data not
shown).
During study follow-up, 28 patients experienced febrile
episodes defined as an oral temperature >99.6◦F for 2
or more consecutive days. In only one of these patients
was the fever attributable to SLE. That patient had non-
renal SLE with extensive skin involvement. Her fevers
subsided when the prednisone was switched from 20 mg
daily to 10 mg twice daily. The other 27 patients expe-
rienced 22 febrile episodes attributed to infection and
five febrile episodes that were unexplained and resolved
spontaneously. Most infections were upper respiratory
tract infections; three infections were pneumonia and re-
quired hospitalization. The incidence of infection fever
was not significantly different between the renal and
nonrenal SLE patients. However, the only severe infec-
tion (histoplasma pneumonia with pulmonary failure) oc-
curred in a renal SLE patient. She recovered completely.
During study follow-up, the patients recorded their
temperature on an average of 90.9 ± 14.7% of days. Tem-
perature was also recorded at 100% of the study clinic vis-
its. The mean study clinic temperature was 97.93 ± 0.71◦F.
The mean temperature recorded by the patient on the
evening of the study clinic visit was 97.91 ± 0.81◦F (P=
0.55, compared to study clinic temperature). The mean
daily study temperature of the patients who relapsed
(N = 51) compared to those who did not relapse (N =
41) was 97.92 ± 0.86◦F compared to 97.88 ± 0.83◦F (P=
0.015). The patients’ mean clinic temperature on relapse
visits versus no-relapse visits was 97.90 ± 0.76◦F com-
pared to 97.93 ± 0.70◦F (P= 0.82).
Study B
Table 3 shows selected demographics and clinical pa-
rameters in the SLE patients who presented with the
fever of SLE or the fever of infection. The key differences
between the groups are lower C3 levels in the patients
with the SLE fever and more frequent use of immunosup-
pressive therapy in the patients with the infection fever.
Table 4 shows the temperature changes in relation to
steroid therapy in the patients with the fever of SLE com-
pared to those with the fever of infection. Figures 3 and
4 depict these changes. Each case is briefly discussed be-
low. The symbols shown in Figures 3 and 4 identify the
individuals described in the cases.
PATIENTS WITH THE FEVER OF SLE
Case 1 (closed triangle)
This woman presented with fever unresponsive to ac-
etaminophen therapy, abdominal pain, red-brown urine,
severe hemoglobinuria due to a an IgG Coombs-positive
hemolytic anemia, and acute renal failure. A detailed
evaluation showed no evidence of infection, and no evi-
dence of cold agglutinin hemolytic anemia. Antibodies
to double-stranded DNA (anti-DNA) were present in a
titer of 1:40. Platelet count was 85,000/cmm. Hemoglobin
was 6.6 g/dL and reticulocyte count 6%. Renal biopsy
showed only acute tubular necrosis. Initially the patient
received methylprednisolone 30 mg intravenously every
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Table 2. Flare rate and classification of systemic lupus erythematosus (SLE) flares during study follow-up
Renal flare ratea Nonrenal flare ratea
Mild Moderate Severe Mild Moderate Severe Flare rate by groupb
Renal SLE (N = 60) 0.084 0.209 0.070 0.251 0.223 0.014 0.851
Nonrenal SLE (N = 32) 0 0 0 0.169 0.271 0.068 0.508
Total flare rate by type 0.059 0.148 0.049 0.227 0.237 0.030 0.75
aFlares per 12 months of follow-up.
bP= 0.062 comparing flare rates between the renal and nonrenal group.
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Fig. 1. Mean daily prednisone dose ± 1 SD in
the renal and nonrenal systemic lupus erythe-
matosus (SLE) patients during study follow-
up. The difference in mean prednisone dose
between the renal and nonrenal patients is sig-
nificant, P < 0.001.
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Fig. 2. Fever trends in the 30 days prior to study visits in which it was
determined that a systemic lupus erythematosus (SLE) flare was present
(flare visit) or not (no flare visit). Fever was defined as study fever (oral
temperature >99.6◦F) or a personal fever (oral temperature ≥ the top
10% of oral temperatures for that person). There is no difference in
fever trends prior to flare visits compared to no flare visits (P= 0.41 for
study fever, P= 0.69 for personal fever).
12 hours. After 48 hours she was switched to prednisone
60 mg daily. Over the ensuing weeks her hematologic, re-
nal, and immunologic abnormalities gradually and com-
pletely corrected.
Case 2 (closed circle)
This woman presented with fever, pleuritic left chest
pain, and chest x-ray film showing a large left pleural
effusion. Her SLE originally presented with membra-
nous nephropathy, which was in remission. Thoracente-
sis showed an exudative effusion based on protein and
lactate dehydrogenase (LDH) content. The cell count
showed 1100 cell/mm3. The differential showed 65%
mononuclear cells, the rest were mainly neutrophils. A
detailed evaluation showed no evidence of infection or
pulmonary embolus. The patient was supposed to be
receiving prednisone 20 mg daily but was taking pred-
nisone only intermittently because she feared progres-
sion of her bilateral osteonecrosis of the femoral heads.
She was placed on prednisone 20 mg daily. She improved
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Table 3. Selected clinical parameters at time of presentation with the systemic lupus erythematosus (SLE) fever or infection fever
Case Years Organs affected White blood Cytotoxic
numbera Age Raceb of SLE by SLEc cellsd cells/mm3 C3e mg/dL C4f mg/dL therapyg
Fever of SLE
1 38 W 9 H 4.4 80 22 0
2 29 W 13 K, Se 15.6 55 9 0
3 29 W 13 K, Se 8.1 31 5 0
4 24 W 10 H, J, K, Sk 2.2 52 14 0
5 35 W 7 E,J,K,Sk 4.8 55 24 0
6 22 W 0 K 5.4 36 9 0
7 21 B 0 H, J, K 3.3 27 9 0
8 28 B 11 H, J, K, Se 3.3 50 6 0
9 22 W 0.5 J, K, Se 9.5 38 8 0
10 42 B 6 H, J, K 4.0 117 38 0
11 31 B 2 J, K, Se 6.3 33 9 M
Mean ± SD 29 ± 7 6.5 ± 5.1 6.1 ± 3.8 52 ± 28h 14 ± 11
Fever of infection
12 32 B 4 J, K, M, Se, Sk 8.0 83 8 A
13 32 B 10 J, K, L, M 4.6 96 9 0
14 16 W 1 J, K, L, M 2.5 105 36 C
15 31 W 5 J, K, Sk 8.4 88 24 C
16 32 W 7 H, L, K 10.6 48 6 0
17 36 B 8 H, J, K, Sk 0.7 119 32 0
18 55 W 8 J, K, Sk 3.9 98 24 A
19 35 W 0.2 H, M 14.5 61 10 0
20 23 W 2 J, K, Sk 10.2 93 25 0
21 28 W 7 J, K, Sk 8.1 113 17 C
22 38 B 0.8 B, K, Sk 14.7 15 <10 0
Mean ± SD 32 ± 10 4.8 ± 3.4 7.8 ± 4.6 83 ± 31h 18 ± 10
aAll cases were female except cases 14 and 19.
bW, Caucasian; B, African American.
cOrgans involved currently or in the past (see individual case reports): B, brain; E, eye; H, hematologic; J, joints; K, kidney; L, lung; M, myocardium; Se, serosa
(pleura and/or pericardium); Sk, skin.
dWhite blood cell count × 10−3 (normal 5.0 to 10.0/mm3).
eNormal 90 to 150 mg/dL.
fNormal 14 to 40 mg/dL.
gA, azathioprine; C, cyclophosphamide; M, methotrexate. This therapy was present at the onset of fever.
hP= 0.029, compared to the mean C3 value of the patients with SLE fever (unpaired t test).
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Fig. 3. Response of systemic lupus erythematosus (SLE) fever to glu-
cocorticoid therapy. In a retrospective analysis, each patient was ascer-
tained to have SLE fever (see case studies). The symbols identify the
individual cases with SLE fever, which described in the case studies.
promptly. Her pleural effusion cleared over the ensuing
weeks.
Case 3 (five-point star)
This is the same patient as described in Case 2. On this
occasion, 16 months after the episode described above,
she presented with fever, pleuritic chest pain, and bilat-
eral pleural effusions by chest x-ray film. Thoracentesis
showed an exudative pleural effusion. A detailed evalua-
tion showed no evidence of infection or pulmonary embo-
lus. The patient had been receiving prednisone 5 mg every
other day. She was placed on prednisone 20 mg twice a
day with prompt resolution of her signs and symptoms.
Case 4 (open circle)
This woman presented with fever and malaise. Platelet
count was 120,000/mm3. Her SLE originally manifested
as malar rash, positive antinuclear antibodies (ANA),
arthralgias, leukopenia, and a renal biopsy showing class
IV glomerulonephritis. At this presentation a detailed
evaluation showed no evidence of infection. Her pred-
nisone dose was increased from 15 mg daily to 25 mg twice
daily. By 24 hours the patient’s symptoms were dramat-
ically improved. Over the ensuring weeks, her abnormal
hematologic findings reverted to normal and she felt well.
Case 5 (closed square)
This patient’s SLE initially manifested as malar
rash, arthralgias, retinal cytoid bodies, positive ANA,
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Table 4. Peak oral temperature while on steroid therapy in patients with systemic lupus erythematosus (SLE) fever or infection fever
Fever of SLE Fever of infection
Steroid dose mgb Steroid dose mgd
Case Peak temperature (◦F) on steroidsa First dose 24-hour dose Case Peak temperature (◦F) on steroidsc First dose 24-hour dose
1 97.4 37.5 75 12 102.6 40 40
2 98.6 25 25 13 101.0 20 80
3 98.4 20 40 14 101.0 240 960
4 98.2 25 50 15 103.0 40 40
5 98.2 30 60 16 101.8 30 120
6 98.0 30 60 17 100.4 50 100
7 97.8 30 60 18 103.0 35 35
8 99.0 25 50e 19 102.4 60 120
9 98.6 40 40 20 102.0 40 40
10 98.0 20 20 21 103.0 300 1800
11 97.5 25 50 22 102.4 60 60
Mean ± SD 98.2 ± 0.5f 28 ± 6g 48 ± 16h 102.0 ± 0.9 83 ± 94 254 ± 413
aPeak oral temperature 18 to 48 hours after initiating or increasing the glucocorticoid therapy.
bThe “first dose” is the initial or increased glucocorticoid dose given in response to fever. This dose is specified because in the patients with the fever of SLE this dose
generally completely resolved fever before the next dose was given. The “24-hour dose” is the total glucocorticoid dose given that day. The glucocorticoid dose is given
in prednisone equivalents (5 mg prednisone = 4 mg methylprednisolone = 25 mg hydrocortisone).
cPeak oral temperature while on glucocorticoid for >3 days and at a dose ≥35 mg daily of prednisone or equivalent dose of another glucocorticoid.
dThe patients with the infection fever had been receiving the indicated dose of glucocorticoid (prednisone equivalents) for >3 days.
eThis patient was receiving therapeutic doses of phenytoin, which increases the metabolism of glucocorticoids by about 50% (see text). The glucocorticoid dose
shown is adjusted for this effect of phenytoin on glucocorticoid metabolism.
fP= 0.001 compared to peak oral temperature on glucocorticoid therapy in those with the fever of infection (Wilcoxan rank sum).
gP= 0.004 compared to first dose of glucocorticoid in those with the fever of infection.
hP= 0.097 compared to 24-hour dose of glucocorticoid in those with the fever of infection.
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Fig. 4. Response of infection fever to glucocorticoid therapy. In a retro-
spective analysis, each patient was ascertained to have infection fever
(see case studies). The symbols identify the individual cases with in-
fection fever described in the case studies. Each of these patients was
receiving moderate or higher steroid doses for 3 or more days at the time
these observations were made. The data shown are typical of the oral
temperatures displayed by these patients during their period of fever.
At no point did the patients with the infection fever show a sustained
reduction in oral temperature, as was consistently seen in the patients
with systemic lupus erythematosus (SLE) fever (Fig. 3.).
anti-DNA antibodies, and class IV glomerulonephritis.
Four months prior to the present febrile illness she ex-
perienced a renal relapse, which was being treated with
a tapering dose of prednisone. When her prednisone
dose reached 20 mg alternating daily with 5 mg she
developed low-grade fever and fatigue. Proteinuria in-
creased from 2.5 to 5.3 g/24 hours. A detailed evaluation
showed no evidence of infection. When her prednisone
dose was increased to 30 mg twice a day, her symptoms
cleared promptly. Over the next several months her pred-
nisone dose was tapered. Her proteinuria declined to
<2 g/24 hours and serum creatinine remained stable at
1.0 mg/dL. She felt well.
Case 6 (open triangle)
This woman presented with fever and heavy protein-
uria. Serum creatinine was 1.4 mg/dL and 24-hourr pro-
teinuria was 10 g. Anti-DNA antibodies were present in
a titer of 1:80. Renal biopsy showed class IV glomeru-
lonephritis. A diagnosis of SLE was made. A detailed
evaluation showed no evidence of infection. Prednisone
30 mg twice a day was begun along with oral cyclophos-
phamide 100 mg daily. Fever disappeared promptly. Her
renal manifestations gradually resolved over the ensuing
6 months.
Case 7 (wheel spokes)
This woman presented with fever unresponsive to ac-
etaminophen therapy, arthralgias, and edema. Serum
creatinine was 1.0 mg/dL, 24-hour urine protein was
12 g. ANA was positive 1:80. Anti-DNA antibodies were
positive 1:160. Renal biopsy showed class IV glomeru-
lonephritis. A diagnosis of SLE was made. A detailed
evaluation showed no evidence of infection. Prednisone
30 mg twice a day was begun along with cyclophos-
phamide 125 mg daily. Her fever and joint symptoms
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decreased dramatically over 24 hours. Her renal mani-
festations gradually cleared over the ensuing year.
Case 8 (asterisk)
This woman presented with fever and arthralgias. Her
SLE originally manifested as polyserositis, fever, myal-
gia, renal manifestations, positive ANA, and anti-DNA
antibodies. Renal biopsy showed class IV changes. At
this presentation, her serum creatinine was 3.0 mg/dL
(increased from 1.3 mg/dL 3 months earlier). A detailed
evaluation showed no evidence for infection. Her gluco-
corticoid dose was increased from prednisone 10 mg daily
to prednisolone 50 mg intravenously every 12 hours. The
relatively high dose of prednisolone was chosen because
she had a seizure disorder and was receiving phenytoin,
which increases the metabolism of glucocorticoids (see
Discussion section). The patient’s symptoms dramatically
improved with 24 hours. However, renal function did not
improve.
Case 9 (open square)
This woman presented with fever unresponsive to ac-
etaminophen therapy, arthralgias, fatigue, and pleuritic
chest pain. ANA was positive 1:160. Urinalysis showed
1+ protein, red cells, and red cell casts. Chest x-ray
film showed a small left pleural effusion. A detailed
evaluation showed no evidence of infection. Prednisone
40 mg daily was begun. The patient’s symptoms cleared
promptly. She remained asymptomatic over the ensuing
months as her prednisone dose was tapered.
Case 10 (bold solid line)
This woman with end-stage renal failure secondary to
class IV glomerulonephritis presented with fever and dif-
fuse joint pain. She had been receiving prednisone 10 mg
daily. A detailed evaluation showed no evidence of infec-
tion. Prednisone was increased from 10 to 20 mg daily.
The patient’s symptoms cleared promptly. She remained
asymptomatic as her prednisone dose was tapered.
Case 11 (dashed line)
This woman presented with fever, arthralgias, and re-
currence of the bilateral pleuritic chest pain which was
her presenting symptom when the diagnosis of SLE with
renal manifestations was established 2 years earlier. The
patient had been receiving prednisone therapy. However,
she stopped the prednisone because of fear of weight gain.
In recent months she had been managed with Plaquenil,
nonsteroidal anti-inflammatory agents, and methotrexate
10 mg orally weekly. A detailed evaluation showed no ev-
idence of infection. Intravenous methylprednisolone 20
mg every 12 hours was begun with dramatic improvement
in her symptoms. She was switched to prednisone 20 mg
daily, which was slowly tapered. This therapy was well
tolerated and controlled all of her SLE manifestations.
SLE PATIENTS WITH FEVER OF INFECTION
Case 12 (closed triangle)
This woman presented with fever for the previous
2 weeks, with oral temperatures ranging from 99 to 101◦F.
For the past 4 years she had been treated with doses
of prednisone ranging from 5 to 60 mg daily along with
azathioprine or cyclophosphamide to control numerous
episodes of active SLE which include skin vasculitis, pan-
creatitis, and myocarditis. Chronic pyoderma gangrenosa
of the lower legs was also present. At the time of this
presentation she was receiving prednisone 15 mg and
azathioprine 50 mg daily. Active SLE was thought to be
the cause of her fever. Her prednisone was increased to
20 mg twice a day. The azathioprine dose was maintained.
Despite the increase in prednisone dose her oral temper-
ature remained elevated. She was hospitalized. An exten-
sive evaluation for infection including multiple blood cul-
tures was negative. However, on week 4 of fever an area
of cellulitis developed over her left lateral thigh. Further
evaluation revealed an underlying abscess which grew
Escherichia coli. The azathioprine was stopped, pred-
nisone decreased to 10 mg, Tobramycin was begun and
surgical drainage of the abscess was undertaken. The pa-
tient rapidly became afebrile and did well over the ensu-
ing months. Despite an extensive diagnostic evaluation,
no primary source for the E. coli infection was found.
Case 13 (open circle)
This woman with a history of severe cardiomyopathy
associated with SLE presented with hemoptysis and bi-
lateral lung infiltrates while receiving prednisone 30 mg
daily. A diagnosis of lupus pneumonitis was made al-
though the patient had no other evidence of active SLE.
The prednisone dose was increased to 30 mg twice a
day and high-dose intravenous diuretic therapy was be-
gun. She improved remarkably over 48 hours. How-
ever, 3 weeks later, severe hemoptysis recurred. Chest x-
ray film showed extensive bilateral pulmonary infiltrates.
A Swan-Ganz catheter was placed showing pulmonary
artery systolic and diastolic pressures of 64 and 32 mm
Hg, respectively. Intravenous diuretics were increased
and she was switched to methylprednisolone 250 mg in-
travenously each 6 hours. The patient then developed
fever. Multiple blood and sputum cultures were ob-
tained but no pathogens were isolated. High-dose steroid
therapy was continued. Azathioprine 100 mg daily was
added. The physicians managing her case believed that
her pulmonary manifestations were the result of lupus
pneumonitis. Her pulmonary status progressively wors-
ened. She died 4 weeks after the institution of high-dose
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glucocorticoid therapy. Just prior to death the patient de-
veloped profound leukopenia and blood cultures became
positive for Pseudomonas, and sputum and urine cul-
tures became positive for torulopsis. An autopsy was not
obtained.
Comment. In retrospect the patient’s initial episode of
hemoptysis probably was the result of congestive heart
failure rather than lupus pneumonitis. Later she devel-
oped a pulmonary infection. This patient’s course is an
example of the danger of maintaining high-dose steroid
therapy in the face of continuing fever.
Case 14 (hexagon)
The SLE in this boy manifested as pericarditis
1 year earlier. This resolved on prednisone therapy. Nine
months later the patient again developed active SLE, this
time with lung infiltrates. A diagnosis of SLE pneumoni-
tis was made. These manifestations cleared dramatically
on prednisone 80 mg daily. However, his signs and symp-
toms of pneumonitis recurred, along with cardiomegaly,
when his prednisone was tapered over 4 weeks to 20 mg
daily. At this point he was begun on prednisone 80 mg
daily and oral cyclophosphamide 150 mg daily. Because
of continuing lung infiltrates and onset of cardiomegaly
he was transferred to the Ohio State University Medi-
cal Center. The cyclophosphamide and high-dose steroid
therapy were continued. He became febrile on the third
week of this therapy. Legionnella was grown from spu-
tum. Blood cultures were negative. Erythromycin ther-
apy was begun. His methylprednisolone was decreased
to 20 mg intravenously every 4 hours and cyclophos-
phamide was reduced to 125 mg daily. His fever con-
tinued. The lung infiltrates progressed, he became ob-
tunded. A computed tomography (CT) scan of the brain
showed numerous lesions. Lumbar puncture showed nor-
mal spinal fluid. Lupus cerebritis was suspected. The
patient progressively deteriorated on high-dose steroid
therapy, broad-spectrum antibiotics, and amphotericin-
B therapy. He died 2 weeks later. Autopsy revealed ex-
tensive aspergillosis involving kidneys, lungs, and brain.
There was no evidence of active SLE.
Comment. This case is another example of adverse
outcome in a patient in whom cytotoxic therapy and high-
dose steroid therapy are continued in the face of fever.
Case 15 (wheel spokes)
This woman developed fever in the sixth week of treat-
ment with high-dose prednisone and cyclophosphamide
which were used to treat a severe relapse of her SLE
nephritis. Renal biopsy showed class IV changes. Dur-
ing the prior 6 weeks the signs of SLE nephritis had
markedly improved and serum C3 had increased from
50 to 88 mg/dL. Infection was suspected as the cause of
the fever because all signs of active SLE were waning,
and the fever developed on high-dose immunosuppres-
sive therapy. Accordingly, the cyclophosphamide was dis-
continued and the prednisone was decreased to 30 mg
daily. A detailed evaluation for infection was negative.
Over the ensuing 2 weeks her fever gradually resolved.
She felt well, and all SLE manifestations continued to im-
prove as her prednisone dose was tapered to maintenance
levels over the next 4 months.
Comment. The cause of the patient’s fever was never
identified but was assumed to be a viral syndrome.
The fever was not likely due to SLE because the fever
emerged during prolonged high-dose steroid therapy, and
at a time when all manifestations of her SLE were re-
solved or resolving. Furthermore, her SLE remained in
remission in the face of a sharp reduction in her cytotoxic
and glucocorticoid therapy.
Case 16 (open square)
This woman presented with coma, seizures, and pro-
gressive lung infiltrates, severe hypertension, oliguria,
and small infarcts of the toes. She was afebrile at pre-
sentation. Platelet count was 34,000/cmm. Two years ear-
lier the patient had a severe flare of SLE characterized
by peripheral neuropathy and myocardial and bowel in-
farctions. These were thought to be the result of emboli
from the endocarditis of Libman and Sacks. That SLE re-
lapse was treated successfully with prednisone. However,
the patient stopped her prednisone about 2 months prior
to the current admission. On admission, the patient was
thought to have SLE vasculitis and was treated with high-
dose intravenous steroids. Phenytoin 400 mg daily was
begun. Her coma cleared, the lung infiltrates resolved,
and the platelet count rose toward normal. She received
methylprednisolone 25 mg intravenously every 6 hours.
On the ninth hospital day she developed fever. A detailed
evaluation was negative for infection. She was treated
empirically with clindamycin, imipenem, and an amino-
glycoside. Her fever persisted. On hospital day 20, she was
noted to be jaundiced. She was taken to surgery where
a necrotic gallbladder was removed. Pathologic exami-
nation of the gallbladder showed vasculitis. Twenty-four
hours after the surgery, the patient became afebrile for
the first time in 3 weeks. She improved steadily and was
discharged on hospital day 45 while receiving prednisone
20 mg daily.
Comment. This patient had both active SLE and
necrotizing cholecystitis at the onset of fever. However,
the fever was likely due to the cholecystitis because the
fever resolved within 24 hours of the cholecystectomy
and as therapy for the SLE was decreased. Infection com-
plicating the necrotizing cholecystitis was never proved,
perhaps because the patient was already receiving broad-
spectrum antibiotic therapy when the cultures of the
gallbladder and bile were taken.
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Case 17 (closed square)
This woman developed a fever to 103◦F while taking
prednisone 20 mg daily for about 4 weeks to treat her
SLE which, as in the past, was manifesting as arthralgias
and malar rash. Because of the high fever she was ad-
mitted to her local hospital. There she received methyl-
prednisolone 40 mg intravenously every 6 hours on the
assumption that the fever was the result of SLE. She
also received an intravenous cephalosporin. Her fever
persisted. She was then transferred to The Ohio State
University Medical Center. On the second hospital day
she complained of pharyngitis. Extensive oral ulcers were
noted. These were positive for herpes simplex by direct
fluorescent antibody testing and by culture of the lesions.
Her glucocorticoid therapy was decreased to prednisone
10 mg daily and she received intravenous acyclovir. Over
the next 4 days she became afebrile and the oral lesions
improved dramatically. At discharge her white blood cells
had increased 4500/mm3. She remained asymptomatic
and afebrile on prednisone 10 mg daily, and with no signs
of active SLE
Comment. The initial cause of this patient’s febrile
illness is not clear. It is possible that she had an un-
recognized bacterial infection, which was eradicated by
the cephalosporin therapy. The severe outbreak of her-
pes simplex could have been a response to that infec-
tion. In any event, the patient was successfully man-
aged by antimicrobial therapy and by sharply decreasing
her immunosuppressive therapy. Her fever and infection
cleared. Her SLE did not flare. This suggests that SLE
was not the cause of her fever.
Case 18 (closed circle)
This woman developed fever and headache after
3 weeks of daily prednisone 40 mg and azathioprine
100 mg, which were begun to treat a flare of her SLE
nephritis. Because of fever and severe headache she was
admitted to The Ohio State University Medical Center.
The azathioprine was discontinued, prednisone was de-
creased to 30 mg daily, and intravenous cephalosporin
was begun. A detailed evaluation for infection, includ-
ing lumbar puncture was unremarkable. She remained
febrile. On the second hospital day, numerous vesicles
were noted on the lower lip. The direct fluorescent anti-
body test for herpes simplex was positive as were cultures
of the lesions. The antibiotic was stopped. Intravenous
acyclovir was begun. Within 48 hours she was afebrile
and showed dramatic improvement of her oral vesicles.
She was discharged on prednisone 10 mg daily. Over the
ensuing months, the renal and serologic manifestations
of SLE continued to improve.
Comment. The interpretation of this case is similar to
that of Case 17.
Case 19 (five-point star)
This man was transferred to The Ohio State Univer-
sity Medical Center with severe manifestations of lupus
myocarditis and congestive heart failure. He also man-
ifested pancytopenia, lymphadenopathy, and anti-DNA
antibodies in a titer of 1:2560. He was treated with methyl-
prednisolone 50 mg intravenously every 12 hours, di-
uretics, and dobutamine. His heart failure symptoms re-
sponded well, however, on hospital day 15, he developed
fever and diffuse myalgias and arthralgias. His methyl-
prednisolone was decreased to 20 mg twice daily and he
was started on intravenous mezlocillin, tobramycin, and
vancomycin. Multiple blood cultures became positive for
methicillin-resistant Staphylococcus aureus just as an ab-
scess appeared in his left upper arm, a former site of an
intravenous line. He was continued on vancomycin and
methylprednisolone. He was discharged on prednisone
30 mg daily with well compensated cardiac status. He
completed 6 weeks of intravenous vancomycin as an out-
patient without event. His SLE manifestations showed
progressive improvement over the ensuing months.
Case 20 (bold solid line)
This woman with quiescent renal manifestation of SLE
developed fever approximately 3 weeks postpartum from
cesarean section, which delivered a healthy infant. She
had been receiving prednisone 10 mg twice a day since
the cesarean section. With the onset of fever, her pred-
nisone dose was increased to 40 mg daily but she remained
febrile. A detailed evaluation did not reveal a source of
infection or evidence of active SLE. A diagnosis of septic
thrombophlebitis complicating her cesarean section was
made. Ciprofloxacin and clindamycin were begun. Her
prednisone dose was decreased to 10 mg daily. On this
regimen her fever and symptoms cleared over 48 hours.
Over the ensuing months, her SLE remained quiescent
on prednisone 10 mg daily.
Case 21 (dotted line)
This woman presented in the 24th week of pregnancy
with hemoptysis. Four weeks earlier prednisone 15 mg
twice daily was begun because of an SLE flare with
skin, joint, and kidney manifestations. The hemoptysis
was thought to be due to lupus pneumonitis. She was
treated with intravenous methylprednisolone 250 mg ev-
ery 6 hours, however, her fever persisted and her lung
infiltrates increased. Bronchiolar lavage obtained on the
first hospital day grew Legionella. Her prednisone dose
was decreased to 10 mg twice daily and erythromycin
therapy was begun. Her fever and lung infiltrates cleared
rapidly. Her SLE did not flare with the reduction in pred-
nisone therapy.
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Case 22 (dashed line)
This woman presented with severe generalized bul-
lous skin lesions, confusion, hematuria, and proteinuria.
Serologic testing and skin and kidney biopsy (class V
changes) confirmed the diagnosis of SLE. She was be-
gun on prednisone 30 mg twice daily. The skin lesions im-
proved markedly and her confusion cleared. However, on
hospital day 13, she developed fever and thrombocytope-
nia, which were thought to be the result of inadequate
treatment of her SLE. Her prednisone dose was increased
to 60 mg every 12 hours for 3 days. Her fever persisted.
Lung infiltrates appeared. Sputum cultures showed a faint
growth of Candida and Aspergillus. Blood cultures were
negative. The methylprednisolone dose was decreased
to 8 mg intravenously twice daily and Amphotericin-
B therapy was begun. However, the patient developed
progressive pulmonary failure and died 8 days later. Au-
topsy showed extensive aspergillosis involving lung, kid-
ney, and brain. There was no evidence of vasculitis of the
lungs.
Comment. This patient is another example of an ad-
verse outcome when fever develops while on high-dose
steroid glucocorticoid therapy, and the high-dose steroid
therapy is continued. Remarkably, the high-dose steroid
therapy was maintained for only a few days after the onset
of fever, and appropriate antimicrobial therapy was be-
gun promptly. Nevertheless, a fatal outcome from sepsis
was not prevented.
DISCUSSION
Study A is the first prospective study of the association
of fever with SLE flare. Other distinguishing features of
study A are the relatively large number of SLE patients
studied (N = 92), and the detailed testing of the study
population. The average study patient recorded oral tem-
perature on 90.9 ± 14.7% of follow-up days, study clinic
temperature was recorded on 100% of the 670 study vis-
its, during an average of 13.2 months of follow-up, and
a detailed prospective database was maintained on each
patient on which the determination of SLE flare or no
flare was based. Study A, however, is not a study of the
natural history of fever. Rather it mainly assesses how the
SLE fever is modified by steroid therapy. Steroids were
taken on 75% of all study visits and 82% of visits at which
an SLE flare was declared.
To search for an association between fever and SLE
flare multiple definitions of fever were tested, including
temperature > than 99.6◦F (study fever) and temperature
≥ than the top 10% of the individual’s recorded temper-
atures (personal fever).
Study A shows that of the 51 patients who experienced
the 73 SLE flares during study follow-up, fever by any def-
inition was associated with SLE flare in only one patient.
It is unlikely that study A underestimated the association
of SLE fever with SLE flare because daily temperature
was taken on the great majority of days. Also, we suggest
that patients experiencing illness are more likely to take
their temperature than those who are feeling well. Also,
study clinic temperature was independently measured at
all study visits. The study clinic temperatures corrobo-
rated the home temperatures. Study A patients, however,
did experience fever. Twenty-eight patients had febrile
episodes (temperature >99.6◦F for 2 or more consecu-
tive days). However, in only one patient was the fever
associated with SLE (discussed in the Results section).
Thus, in our SLE cohort, infection was far more likely
than SLE to account for fever.
The historic descriptions of SLE fever indicate a much
stronger association of fever with SLE flare than that
described by study A [3]. We suggest that the discrep-
ancy is explained by the general use of steroids in study
A patients. The patients recruited to the OSS were se-
lected on the basis of severe and recurrently active dis-
ease. Thus, steroids were generally needed for manage-
ment. NSAIDs may also play a role in blunting the fever
of SLE [2]; however, in our study none of the renal SLE
patients were receiving NSAIDS but 90% were receiving
steroid therapy. None of the renal SLE patients experi-
enced fever with SLE flare. Thus lack of SLE fever in
study A is best explained by chronic maintenance steroid
therapy.
Study B further tested the hypothesis that SLE fever
is readily suppressed by steroid therapy, whereas infec-
tion fever is not. Study B retrospectively examined the
outcome of fever in 22 febrile SLE patients who initially
received moderate to high-dose steroid therapy for an
illness that was thought to be an acute SLE flare. How-
ever at final analysis only 11 of the 22 patients had SLE
fever, the other 11 had infection fever. The SLE pa-
tients with SLE fever experienced complete remission
of fever within 24 to 48 hours after receiving moderate-
dose steroid therapy. By contrast, the SLE patient with
infection fever did not experience remission of fever de-
spite receiving much larger steroid doses. Thus study B
corroborates the finding of study A that steroids readily
suppress SLE fever but not infection fever.
The reason for the greater resistance of infection fever
to steroid therapy is not clear. Fever is caused in part by
the central nervous system effects of prostaglandin E2
[14] and the cytokines interleukin (IL)-1b , tumor necro-
sis factor-a (TNF-a), IL-6, and interferon (INF)a, INF-b ,
and INF-c [6, 15, 16], all of which are produced by ac-
tivated macrophages/monocytes [17]. Steroids suppress
macrophage/monocyte function [18, 19]. It is plausible
that fewer macrophages/monocytes are involved in ac-
tive SLE compared to serious systemic infections. If that
is the case, steroid therapy would be expected to be less
effective in suppressing monocyte/macrophage function
in infection compared to active SLE.
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The observation that moderate steroid doses should be
sufficient to control the fever of SLE applies to patients
not receiving drugs that can increase steroid metabolism.
These drugs include phenobarbital [20, 21], phenytoin
[22, 23], rifampin [24–27], and carbamazepine [28–31].
Each of these drugs induces the hepatic P-450 system to
increase steroid metabolism thereby decreasing its bio-
logical effects. Patients receiving these drugs usually re-
quire at least a twofold increase in their steroid dose to
maintain steroid efficacy [25].
The present report also suggests that there is danger in
prolonging high-dose steroid therapy in the SLE patients
whose fever persists on high-dose steroids (equivalent
to prednisone ≥60 mg daily). Others have incidentally
reported similar observations [7–9].
The number of study B patients is not sufficient to pre-
cisely estimate the sensitivity and specificity for steroid
effects on SLE fever compared to infection fever. Never-
theless, they provide strong support for the general rec-
ommendation that if fever emerges in an SLE patient
already receiving prednisone 20 to 40 mg daily, it is likely
that that fever is due to infection, not active SLE. Simi-
larly, if fever fails to resolve in an SLE patients receiving
prednisone 20 to 40 mg daily, it is likely that that fever is
due to infection, not SLE.
Other findings that favor the diagnosis of infection
fever over SLE fever include the presence of shaking
chills, leukocytosis (especially in the absence of steroid
therapy) [4], neutrophilia, and the presence of increased
numbers of band forms or metamyelocytes [4, 5, 32],
and concomitant immunosuppressive therapy (present
report). Findings that favor the diagnosis of SLE fever
over infection fever include leukopenia (not explained
by cytotoxic therapy), normal or only slightly increased
C-reactive protein (reviewed in [2]), low C3 and C4, and
elevated anti-DNA antibodies [4, 5].
The present work should help the clinician to more ac-
curately differentiate the SLE fever from infection fever.
This differentiation could critically impact patient out-
come.
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